NextCure effects 1:12 reverse stock split effective July 14, 2025

NextCure, Inc.

Reverse stock split ratio 1:12, effective 12:01 a.m. ET on July 14, 2025.
Stockholders approved split ratio range of 1:5 to 1:15; Board chose 1:12.
No fractional shares; cash payment for fractional shares based on closing price prior to effective date.
Authorized shares remain 100 million; all outstanding options, warrants, and equity plans adjusted proportionally.
Common stock continues trading under ticker NXTC on Nasdaq Global Select Market.

item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

NextCure, Inc.: Amendment to Certificate of Incorporation to effect a 1:12 reverse stock split (effective 2025-07-14).

Change: charter amendment
Effective: 2025-07-14

Exact text from the filing

On July 14, 2025, NextCure, Inc., a Delaware corporation (the “ Company ”), effected a one-for-twelve (1:12) reverse stock split (“ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 (the “ Common Stock ”).

View on SEC.gov

Browse all governance changes →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-009214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.